Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing 400038, PR China.
Cell Biol Int. 2009 Nov;33(11):1180-3. doi: 10.1016/j.cellbi.2009.08.007. Epub 2009 Aug 28.
Orthotopic liver transplantation is, to date, the only proven effective treatment for end-stage liver disease. However, it suffers from lack of donors and immunorejection. Here, we speculate that co-transplantation of induced pluripotent stem (iPS) cells derived hepatocytes and mesenchymal stem cells (MSCs) may offer an alternative way to treat patients with end-stage liver disease. Recently, progress on iPS cells, homogeneous differentiation of hepatocyte-like cells from embryonic stem cells (ESCs), and paracrine effects by MSCs highlight the possibility. Safe, efficient and rapid generation of iPS cells has been reliably produced by several experimental laboratories. Methods for highly efficient and homogeneous differentiation of ESCs into functional hepatocytes have been established as well. Moreover, paracrine effects by MSCs have been proven to play an important role in liver regeneration and repair, and the effects can be used as an enhancer for engraftment. All of these remarkable developments lead to this hypothesis which may offer a novel therapeutic strategy for treatment of patients with end-stage liver disease, though some issues about safety and efficacy need to be further guaranteed.
截至目前，肝移植是治疗终末期肝病的唯一有效方法。但是，这种方法存在供体缺乏和免疫排斥的问题。在这里，我们推测诱导多能干细胞（iPS 细胞）衍生的肝细胞和间充质干细胞（MSCs）的共移植可能为治疗终末期肝病患者提供一种替代方法。最近，iPS 细胞、胚胎干细胞（ESCs）向肝样细胞的同质分化以及 MSCs 的旁分泌作用方面的进展突出了这种可能性。几个实验实验室已经可靠地产生了安全、高效和快速的 iPS 细胞生成方法。高效且同质分化 ESCs 为功能性肝细胞的方法也已经建立。此外，MSCs 的旁分泌作用已被证明在肝再生和修复中发挥重要作用，并且这种作用可作为植入增强剂。所有这些显著的发展都导致了这一假设，即可能为治疗终末期肝病患者提供一种新的治疗策略，尽管需要进一步保证安全性和有效性方面的一些问题。
